KIF2C and paraganglioma: A recent pan-cancer study analyzing the mRNA levels of KIF2C in various TCGA cancers revealed its widespread high expression across multiple cancer types, including BRCA, kidney renal papillary cell carcinoma, PRAD, OV, LIHC, UCEC, THYM, READ, UCS, DLBC, pheochromocytoma and paraganglioma, SKCM, brain lower grade glioma, CHOL, COAD, STAD, bladder urothelial carcinoma, head and neck squamous cell carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, ESCA, kidney renal clear cell carcinoma, and ACC (58).